AZ’s Imfinzi on target in small cell lung cancer, sets up Roche rivalry

AstraZeneca’s Imfinzi cancer immunotherapy has hit the mark in a phase 3 trial in extensive-stage small cell lung cancer, setting up a potential rivalry with Roche’s PD-L1 class drug Tecentriq (atezolizumab).